| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| S Ezza. Hepatobiliary and gastrointestinal manifestations of acromegaly. Digestive diseases (Basel, Switzerland). vol 10. issue 3. 1992-07-30. PMID:1611713. |
acromegaly is a unique condition characterized by chronic growth hormone (gh) and insulin-like growth factor-1 (igf-1) hypersecretion usually due to a pituitary adenoma. |
1992-07-30 |
2023-08-11 |
Not clear |
| S Ezza. Hepatobiliary and gastrointestinal manifestations of acromegaly. Digestive diseases (Basel, Switzerland). vol 10. issue 3. 1992-07-30. PMID:1611713. |
rarely, acromegaly can result from a gh-releasing hormone carcinoid or pancreatic neoplasm which stimulates the normal pituitary to secrete gh. |
1992-07-30 |
2023-08-11 |
Not clear |
| N Iwatani, M Kodama, T Miik. Endocrinological evaluation of GH deficient patient with acromegaloidism showing excessive growth. Endocrinologia japonica. vol 39. issue 1. 1992-07-22. PMID:1606921. |
she had large and coarse facial features with acral enlargement accompanying height overgrowth; these resemble the manifestations of acromegaly and gigantism due to growth hormone (gh) overproduction. |
1992-07-22 |
2023-08-11 |
Not clear |
| A Giustina, C Bodini, M Doga, M Schettino, G Pizzocolo, G Giustin. Galanin decreases circulating growth hormone levels in acromegaly. The Journal of clinical endocrinology and metabolism. vol 74. issue 6. 1992-06-29. PMID:1375598. |
in acromegaly, circulating gh levels are elevated, and gh secretory dynamics are usually abnormal. |
1992-06-29 |
2023-08-11 |
human |
| A Giustina, C Bodini, M Doga, M Schettino, G Pizzocolo, G Giustin. Galanin decreases circulating growth hormone levels in acromegaly. The Journal of clinical endocrinology and metabolism. vol 74. issue 6. 1992-06-29. PMID:1375598. |
the cause of this paradoxical gh fall after galanin treatment in acromegaly remains to be explained. |
1992-06-29 |
2023-08-11 |
human |
| L Fiszlejder, O Penacini, S Ratz, M Storani, A Oneto, A Guitelma. Effects of pirenzepine, bromocriptine and their association on basal and GHRH- and TRH-induced GH secretion in acromegaly. Hormone research. vol 36. issue 1-2. 1992-06-22. PMID:1814801. |
effects of pirenzepine, bromocriptine and their association on basal and ghrh- and trh-induced gh secretion in acromegaly. |
1992-06-22 |
2023-08-11 |
Not clear |
| L Fiszlejder, O Penacini, S Ratz, M Storani, A Oneto, A Guitelma. Effects of pirenzepine, bromocriptine and their association on basal and GHRH- and TRH-induced GH secretion in acromegaly. Hormone research. vol 36. issue 1-2. 1992-06-22. PMID:1814801. |
in order to ascertain if pirenzepine (pz), an antimuscarinic drug, could inhibit gh secretion in acromegaly, 8 patients were submitted to 3 successive treatment courses of 9 days each: pz, bromocriptine (brc) and pz plus brc. |
1992-06-22 |
2023-08-11 |
Not clear |
| L Fiszlejder, O Penacini, S Ratz, M Storani, A Oneto, A Guitelma. Effects of pirenzepine, bromocriptine and their association on basal and GHRH- and TRH-induced GH secretion in acromegaly. Hormone research. vol 36. issue 1-2. 1992-06-22. PMID:1814801. |
in conclusion, cholinergic control of gh secretion is altered in acromegaly. |
1992-06-22 |
2023-08-11 |
Not clear |
| H Rau, P H Althoff, K Schmidt, K H Usade. Bromocriptine treatment over 12 years in acromegaly: effect on growth hormone and prolactin secretion. Acta endocrinologica. vol 126. issue 3. 1992-06-02. PMID:1574954. |
to elucidate this problem, the secretory gh and prl states of 12 patients with acromegaly were determined, before bromocriptine treatment, under therapy (15.0 +/- 6.8 mg/day for 12 +/- 3 years; mean +/- sd) and during two-weeks long drug withdrawal after long-term treatment, respectively. |
1992-06-02 |
2023-08-11 |
Not clear |
| N Møller, O Schmitz, J O Jøorgensen, J Astrup, J F Bak, S E Christensen, K G Alberti, J Week. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. The Journal of clinical endocrinology and metabolism. vol 74. issue 5. 1992-05-26. PMID:1569148. |
to further assess basal and insulin stimulated fuel metabolism in acromegaly six patients with monotropic gh excess were each studied approximately 1 month prior to and 2 months after successful selective pituitary adenomectomy and compared to a control population of seven subjects. |
1992-05-26 |
2023-08-11 |
human |
| N Møller, O Schmitz, J O Jøorgensen, J Astrup, J F Bak, S E Christensen, K G Alberti, J Week. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. The Journal of clinical endocrinology and metabolism. vol 74. issue 5. 1992-05-26. PMID:1569148. |
when compared to the control subjects the patients with acromegaly were preoperatively and in the basal state characterized by: 1) increased circulating concentrations of gh, insulin, and c-peptide (p less than 0.05); 2) increased plasma glucose (5.9 +/- 0.2 vs. 5.2 +/- 0.2 mmol/l), blood lactate (710 +/- 90 vs. 580 +/- 70 mumol/l), glucose turnover (2.34 +/- 0.12 vs. 1.93 +/- 0.12 mg/kg/min), and plasma lipid intermediates and a decreased forearm glucose uptake (0.06 +/- 0.02 vs. 0.19 +/- 0.04 mmol/l) (p less than 0.05); and 3) a 20% increase in energy expenditure, a 50% elevation of lipid oxidation rates, and a 130% elevation of nonoxidative glucose turnover (p less than 0.05). |
1992-05-26 |
2023-08-11 |
human |
| M Buchfelder, S Brockmeier, R Fahlbusch, J Honegger, J Pichl, M Manz. Recurrence following transsphenoidal surgery for acromegaly. Hormone research. vol 35. issue 3-4. 1992-05-14. PMID:1806464. |
it is concluded that recurrence of active acromegaly is unlikely to occur in patients who achieve a normal glucose-induced suppression of gh levels shortly after adenomectomy. |
1992-05-14 |
2023-08-11 |
human |
| K D Hopkins, I M Holdawa. Insulin secretion and insulin-like growth factor-I levels in active and controlled acromegaly. Clinical endocrinology. vol 36. issue 1. 1992-05-12. PMID:1559300. |
we examined the contributions of growth hormone (gh) and insulin-like growth factor-i (igf-i) to insulin sensitivity and beta-cell function in acromegaly. |
1992-05-12 |
2023-08-11 |
Not clear |
| K Y Ho, J J Kell. Role of growth hormone in fluid homeostasis. Hormone research. vol 36 Suppl 1. 1992-05-12. PMID:1806484. |
the antinatriuretic properties of gh may be of pathophysiological significance in acromegaly, where increased body sodium and plasma volume occur, and may contribute to the development of hypertension in this condition. |
1992-05-12 |
2023-08-11 |
human |
| W Saege. Effect of drugs on pituitary ultrastructure. Microscopy research and technique. vol 20. issue 2. 1992-04-23. PMID:1547357. |
dopamine agonists and somatostatin reduce the tumor size of varying proportions of gh secreting adenomas in acromegaly. |
1992-04-23 |
2023-08-11 |
human |
| b' C Campino, J Szecowka, J M Lopez, J Mulchahey, M Ser\\xc3\\xb3n-Ferr\\xc3\\xa. Growth hormone (GH) receptor antibodies with GH-like activity occur spontaneously in acromegaly. The Journal of clinical endocrinology and metabolism. vol 74. issue 4. 1992-04-22. PMID:1548336.' |
growth hormone (gh) receptor antibodies with gh-like activity occur spontaneously in acromegaly. |
1992-04-22 |
2023-08-11 |
human |
| J Trouillas, G Sassolas, B Loras, B Velkeniers, M Raccurt, L Chotard, F Berthezène, J Tourniaire, C Giro. Somatotropic adenomas without acromegaly. Pathology, research and practice. vol 187. issue 8. 1992-04-02. PMID:1792190. |
these tumors do not secrete enough gh to increase serum levels and cause acromegaly. |
1992-04-02 |
2023-08-11 |
Not clear |
| P Pagesy, J Y Li, M Kujas, F Peillon, O Delalande, A Visot, P Derom. Apparently silent somatotroph adenomas. Pathology, research and practice. vol 187. issue 8. 1992-04-02. PMID:1792191. |
we describe here 9 patients with somatotroph adenomas associated with mild features of acromegaly and basal plasma gh levels in the normal range. |
1992-04-02 |
2023-08-11 |
Not clear |
| J Larrañaga, E Carbó, C Horcajada, J L Herrera Pomb. [Study on the activity of acromegaly: evaluation of IGF-I]. Revista clinica espanola. vol 188. issue 3. 1992-03-06. PMID:1780511. |
the evaluation of acromegaly only with gh levels can be difficult. |
1992-03-06 |
2023-08-11 |
Not clear |
| H Watanobe, S Sasaki, K Takeb. Failure to confirm a growth hormone-releasing activity of corticotropin-releasing hormone in acromegaly: comparison with the effects of other hypothalamic hormones. Acta endocrinologica. vol 125. issue 5. 1992-02-05. PMID:1759537. |
we re-examined whether crh stimulates gh secretion in acromegaly. |
1992-02-05 |
2023-08-11 |
human |